Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVL-3288 and Nicotine for Attention
NCT03281694Phase 1Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of AVL-3288 in schizophrenia and Alzheimer's disease (AD), sponsored by University of Maryland, Baltimore. Primary endpoints: Spatial Attentional Resource Allocation Task reaction time, Spatial Attentional Resource Allocation Task omission errors and 4 more. Planned start May 2018; status: withdrawn.
02
Drugs
AVL-3288
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03281694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281694.